T. Rowe Price Associates
AVLN

T. Rowe Price Associates’s Avalyn Pharma AVLN Stock Holding History

T. Rowe Price Associates’s Portfolio AVLN Stock Details AVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.1M Buy
+1,735,231
New +$50.1M 0.01% 851

Other funds holding AVLN

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

T. Rowe Price Associates's AVLN Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Avalyn Pharma (AVLN) in Q2 2026: 1,735,231 shares worth $57.1M. The stake represents 0.01% of the portfolio and ranks #851 among its holdings.

81 funds tracked by Wall St. Rank hold AVLN as of Q2 2026.

  • T. Rowe Price Associates held 1,735,231 shares of Avalyn Pharma worth $57.1M as of Q2 2026.
  • Avalyn Pharma was a new T. Rowe Price Associates position in Q2 2026.
  • Avalyn Pharma made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #851 holding.
  • 81 funds tracked by Wall St. Rank held Avalyn Pharma as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.